INO Inovio Pharmaceuticals, Inc. logo

INO Inovio Pharmaceuticals, Inc.

Healthcare
$1.35+1.50%ClosedMarket Cap: $72.3M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

PEG

P/B

153.74

P/S

0.00

EV/EBITDA

-0.65

DCF Value

$0.07

FCF Yield

-115.5%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-666.5%

ROA

-170.6%

ROIC

-567.1%

Financials

View All
PeriodRevenueNet IncomeEPS
Q1 null$0.00$-19.7M$
Q4 null$0.00$3.8M$
FY null$65.3K$-84.9M$
Q3 null$0.00$-45.5M$

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$18.50

Target (Median)

$14.00

Target Range

$6.00 - $40.00

2 Strong Buy2 Buy2 Hold0 Sell0 Strong Sell
Piper SandlerOverweight
2025-11-14
HC Wainwright & Co.Neutral
2025-08-14

Trading Activity

Insider Trades

View All
Zoth Lota S.director
SellThu May 21
Zoth Lota S.director
SellThu May 21
YARNO WENDY Ldirector
SellThu May 21
YARNO WENDY Ldirector
SellThu May 21
Weiner David B.director
SellThu May 21

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

US

Exchange

Beta

1.44

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, such as head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, including recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); and Lassa fever. Its partners and collaborators include ApolloBio Corp., AstraZeneca, Beijing Advaccine Biotechnology Co., Ltd., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), Department of Defense (DoD), HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. The company has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support investigational DNA vaccine INO-4800 for COVID-19; and a partnership with International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.

Peers